Hi gmutton,
I checked on this. Actually,R&D rebate inflows are part of reported cash from operations, hence cash burn.
So no real relieve onthis front.
How do you see thefollowing from the F-1 filing:
“Costs incurred outsideAustralia in connection with our future clinical trials are generally noteligible for cash incentives under the R&D Scheme.”
That was new to me.
So the USD 16 MN / AUD 23 MN in R&D rebatesreceived over the two financial years from Jul 2019 to Jun 2021 for the P2b waslimited to the costs incurred inside Australia? Despite the P2b been run in 10countries?
If so, the cash inflow from R&D rebates withrespect to the ongoing P3 should be rather negligible, I guess.
What do I miss?
Hi gmutton, I checked on this. Actually,R&D rebate inflows are...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.010(2.27%) |
Mkt cap ! $553.9M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.5¢ | 43.5¢ | $417.7K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9400 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 26000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |